Atopic dermatitis (AD), also known as (atopic) eczema, is a chronic, relapsing inflammatory skin disease marked by severe pruritus and skin irritation which can have a strong negative impact on patients’ quality of life, in particular in moderate and severe patients. Standard treatments for AD attempt to reduce inflammation and pruritus with combinations of emollients, topical corticosteroids, and topical immunomodulators. Additionally, systemic immunomodulators, and in some cases UV phototherapy, are used to treat AD. Treatment with topical therapies and anti-inflammatory agents is often successful; however, more-effective therapies for treatment-refractory AD represent an area of tremendous unmet need.

Questions Answered in This Report:

  • The pathophysiology of AD is complex, and understanding the interplay between skin barrier defects and immune system reactivity is key to advancing the development of new treatments. How is experts’ understanding of AD pathophysiology evolving? What are promising new drug targets?

  • AD is a highly prevalent disease, and, particularly for severe patients, disease burden can be high. What is the size of the U.S. and EU5 AD patient population and how will it change through 2024? What are the key AD subpopulations?

  • Emollients and topical corticosteroids are standards of care in the treatment of AD. What is the current medical practice for management and treatment of AD patients?

  • Interviewed experts report several remaining unmet needs in the treatment of AD. What unmet needs do physicians expect will be addressed by mid- to late-stage emerging therapies for AD?

  • Commercial interest in AD is high. Which emerging therapies are in clinical development? ?What are the key primary and secondary clinical end points on which emerging therapies are tested? ?Which emerging therapies are likely to launch in the near- to mid-term? In which patient populations will these drugs be used?

Scope:

Market covered: United States, France, Germany, Italy, Spain, and the United Kingdom.

Primary research: 8 country-specific interviews with AD dermatologists and allergists.

Epidemiology: Total prevalence, total prevalence by severit.

Emerging therapies: Phase III: 2 drugs; Phase II: 17.

Author(s): Ian Love, Ph.D.
Wouter van der Pluijm, M.P.H.